Guangxi LiuYao Group Co., Ltd (SHA:603368)
16.77
-0.57 (-3.29%)
Nov 17, 2026, 3:00 PM CST
Guangxi LiuYao Group Revenue
Guangxi LiuYao Group had revenue of 5.62B CNY in the quarter ending September 30, 2026, with 2.94% growth. This brings the company's total for the last twelve months to 21.31B, up 1.74% year-over-year. In the year 2025, Guangxi LiuYao Group had annual revenue of 20.93B, down -1.21%. That makes Guangxi LiuYao Group the 3,659th largest company in the world by revenue and 457th in China.
Revenue (ttm)
21.31B
Revenue Growth
+1.74%
P/S Ratio
0.32
Revenue / Employee
3.79M
Employees
5,627
Market Cap
6.51B
Revenue by Segment
- Wholesale 16.01B 76.8%
- Retail 3.64B 17.5%
- Industrial 1.18B 5.7%
Fiscal year ended Dec 31, 2025 See the full Guangxi LiuYao Group breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.93B | -256.18M | -1.21% |
| Dec 31, 2024 | 21.18B | 370.55M | 1.78% |
| Dec 31, 2023 | 20.81B | 1.76B | 9.23% |
| Dec 31, 2022 | 19.05B | 1.92B | 11.19% |
| Dec 31, 2021 | 17.13B | 1.47B | 9.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jointown Pharmaceutical Group | 171.51B |
| C.Q. Pharmaceutical Holding | 80.51B |
| China National Accord Medicines Corporation | 73.36B |
| China National Medicines Corporation | 53.69B |
| China Meheco Group | 34.46B |
| Shanghai C&D INNOSTIC Medical Technology Group | 19.44B |
| Liaoning Cheng Da | 8.55B |
| Qingdao Baheal Medical INC. | 7.10B |